Key facts
- It has raised $141.2M; the latest was Later Stage VC ($56.2M) in Nov 2025.
- Notable investors include Northern Light Venture Capital, Shenzhen Yifeng Investment Management Enterprise, Xiamen C&D Corporation, GDD Industry Fund, Taikun Fund — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Kind Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Kind Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kind Pharmaceutical
Develoepr of drugs and treatments designed for kidney disease and cancer. The company's main research project is the self-developed oral small-molecule compound, which is primarily used to treat anemia associated with chronic kidney disease. providing patients with effective treatment for the kidneys.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Website
- kindpharmaceutical.com/
- Ownership
- Privately Held (backing)
Kind Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kind Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kind Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.